The global biopharmaceutical CMO and CRO market was valued at USD 30.1 billion in 2020 and is expected to rake around USD 60.1 billion by 2030 with a CAGR of 7.6% during the forecast period 2022 to 2030.
The global biopharmaceutical CMO and CRO market was valued at USD 30.1 billion in 2020 and is expected to rake around USD 60.1 billion by 2030 with a CAGR of 7.6% during the forecast period 2022 to 2030.
Growth Factors
There was unprecedented growth in 2020 due to the COVID-19 pandemic. The rising investments in the biopharmaceutical industry by the prominent participants to enhance their productivity and efficiency have driven the bio manufacturers to increase their focus on outsourcing activities. Currently, biopharma companies have begun outsourcing the resource and capital-intensive steps and, in a few cases, the entire chain of biomanufacturing, thereby boosting the demand for contract-based services.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39095
The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs. However, these CMOs & CROs are expected to face competition from in-house departments of pharmaceutical & biotechnology companies. Several big pharma companies like Novartis announced to maintain and expand their biomanufacturing processes in-house over the coming years.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 60.1 billion by 2030 |
| Growth Rate | CAGR of 7.6% From 2022 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Source, Service, Product |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | BoehringerIngelheim GmbH; Lonza Group AG; Inno Biologics SdnBhd; Rentschler Biopharma SE; JRS Pharma; Biomeva GmbH; ProBioGen AG; Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Toyobo Co., Ltd.; Samsung Biologics |
By Source Analysis
The mammalian segment held the highest market share of more than 55% in 2021 owing to the lack of internal expertise in the industry. This is attributed to their capabilities to add human-like post-translational modifications to complex protein therapeutics.
These developments have led to more productive and efficient manufacturing of biologics using mammalian cells. Non-mammalian cell lines, such as microbial cell lines, are recognized as potent factories. Innovative strategies are being implemented to identify and explore the potential of various microbes.
Get more information@ https://www.visionresearchreports.com/report/enquiry/39095
By Service Analysis
The contract research segment is expected to exhibit the fastest CAGR of 7.5% over the forecast period owing to the increasing outsourcing of research activities by biopharmaceutical companies.
These factors have resulted in the largest share of this segment. On the other hand, CROs are striving to capitalize on the potential avenues in the industry.
By Product Analysis
The biologics segment dominated the market with the largest revenue share of over 81% in 2021. This growth is attributed to the high specificity of biologics, complex manufacturing steps, and a higher success rate as compared to other drug molecules.
Several companies are investing in biosimilar development to outperform the safety, efficacy, disposition, or cost of earlier in-class innovator drugs. This has increased the level of competition amongst innovator manufacturers, which in turn, is likely to benefit the CMOs.
By Regional Analysis
North America held the largest revenue share of 33.97% in 2021. This can be attributed to the local presence of several service providers in the region. Also, a significant number of approved products in the U.S. are being manufactured by CMOs.
The key reason for the rise in outsourcing in Asian countries includes cost-associated benefits, such as lower labor costs and operating costs across the region.
Key Players
- BoehringerIngelheim GmbH
- Lonza Group AG
- Inno Biologics SdnBhd
- Rentschler Biopharma SE
- JRS Pharma
- Biomeva GmbH
- ProBioGen AG
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Toyobo Co., Ltd.
- Samsung Biologics
Market Segmentation
- By Source
- Mammalian
- Non-mammalian
- By Service Type
- Contract Manufacturing
- Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC Studies
- Packaging
- Process Development
- Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
- Contract Manufacturing
- By Product
- Biologics
- Monoclonal antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
- Biologics
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39095
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333